UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000008584
Receipt number R000010083
Scientific Title Brain Assessment and Investigation in Heart Failure Trial
Date of disclosure of the study information 2012/07/31
Last modified on 2021/08/15 23:50:22

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Brain Assessment and Investigation in Heart Failure Trial

Acronym

B-HeFT

Scientific Title

Brain Assessment and Investigation in Heart Failure Trial

Scientific Title:Acronym

B-HeFT

Region

Japan


Condition

Condition

Patients with Stage B and C heart failure by ACC-AHA guidelines

Classification by specialty

Medicine in general Cardiology Neurology
Psychosomatic Internal Medicine Geriatrics Psychiatry
Radiology Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The purpose of this study is to investigate a possible influence of heart failure on brain functions and structures such as cerebral blood flow (CBF) using brain and cardiac magnetic resonance imaging (MRI).

Basic objectives2

Others

Basic objectives -Others

Cerebral blood flow (CBF) is measured by arterial spin labeling (ALS) perfusion imaging.
Analysis of CBF is performed using the statistical parametric mapping software (SPM8, the Wellcome Trust Centre for Neuroimaging, London, UK) implemented in MATLAB (Mathworks Inc, Natick, MA, USA).

Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

(1) Cerebral blood flow (CBF)
Comparison between Stage B patients and Stage C patients.

Key secondary outcomes

(2) CBF
It is analyzed whether CBF is associated with cardiac index (CI), total brain volume (TBV), grey matter (GM), white matter (WM), white matter hyperintensities (WMI) and/or intima media thickness (IMT).

(3) TBV, GM and WM
It is analyzed whether TBV, GM and/or WM are associated with CI, WMH and/or IMT.

(4) WMH
It is analyzed whether WMH is associated with CI and/or IMT.

(5) IMT
It is analyzed whether IMT is associated with CI.

(6) Depressive symptoms evaluated by Beck depression Inventory (BDI) and geriatric depression scale (GDS).
(7) Cognitive function and mild cognitive impairment (MCI) evaluated by mini-mental state examination (MMSE), frontal assessment battery (FAB) and Wechsler memory scale-reviced (WMS-R).
(8) Quality of life (QOL) evaluated by Minnesota living with heart failure questionnaire.

In (6)-(8), it is analyzed whether depressive symptoms, cognitive function, MCI and/or QOL are associated with CBF, CI, TBV, GM, WM, WMH and/or IMT.

(9) Blood unsaturated fatty acid (omega-3 fatty acids, omega-6 fatty acids, alpha-linolenic acid, docosahexaenoic acid and eicosapentaenoic acid)
(10) Blood brain derived neurotrophic factor (BDNF)
(11) Blood amyloid beta (A-beta 40 and A-beta 42)

In (9)-(11), it is analyzed whether unsaturated fatty acid, BDNF and/or amyloid beta are associated with CBF, CI, TBV, GM, WM, WMH and/or IMT.

In (2), comparison among Stage B/C patients with ischemic/nonischemic heart diseases, comparison between patients with heart failure with reduced ejection fraction (HFREF) and patients with heart failure with preserved ejection fraction (HFPEF) and comparison among NYHA classes are analyzed.

In (3)-(11), comparison between Stage B patients and Stage C patients, comparison among Stage B/C patients with ischemic/nonischemic heart diseases, comparison between patients with HFREF and patients with HFPEF and comparison among NYHA classes are analyzed.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

45 years-old <=

Age-upper limit

90 years-old >

Gender

Male and Female

Key inclusion criteria

Patients with Stage B and C heart failure by ACC-AHA guidelines with a written informed consent.

Key exclusion criteria

(1) Contraindication of MRI:
Cardiac devices or claustrophobia.

(2) Unstable cardiac function:
Patients who had uncontrolled heart failure or required intravenous inotropes.

Patients receiving stent implantation for acute myocardial infarction
within 3 months.

(3) Past history significantly affecting cerebral blood flow and/or brain structure:
MMSE < 24, mental retardation, neurodegenerative disease, psychiatric disorder, epilepsy, symptomatic stroke, symptomatic carotid stenosis with or without stenting or endarterectomy, head trauma, hydrocephalus, intracranial mass, alcohol/drug addiction, hypo/hyperthyroidism, aortic stenosis proximal to left cervical artery and/or severe aortic valve stenosis.

(4) Difficulty in evaluating brain and/or cardiac MRI:
Artifacts of movements or other causes.

Patients with complex congenital heart diseases.

Target sample size

80


Research contact person

Name of lead principal investigator

1st name Hideaki
Middle name
Last name Suzuki

Organization

Tohoku University Hospital

Division name

Department of Cardiovascular Medicine

Zip code

980-8574

Address

1-1, Seiryo, Aoba, Sendai, Japan

TEL

+81-22-717-7153

Email

hd.suzuki.1870031@cardio.med.tohoku.ac.jp


Public contact

Name of contact person

1st name Hideaki
Middle name
Last name Suzuki

Organization

Tohoku University Hospital

Division name

Department of Cardiovascular Medicine

Zip code

980-8574

Address

1-1, Seiryo, Aoba, Sendai

TEL

+81-22-717-7153

Homepage URL


Email

hd.suzuki.1870031@cardio.med.tohoku.ac.jp


Sponsor or person

Institute

Department of Cardiovascular Medicine

Institute

Department

Personal name



Funding Source

Organization

Tohoku University Hospital

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethics Committee Tohoku University Hospital

Address

1-1, Seiryo, Aoba, Sendai, Japan

Tel

+81-22-717-3964

Email

ec@rinri.hosp.tohoku.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2012 Year 07 Month 31 Day


Related information

URL releasing protocol

https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&recptno=R000010083&ty

Publication of results

Published


Result

URL related to results and publications

http://www.ncbi.nlm.nih.gov/pubmed/27295999

Number of participants that the trial has enrolled

80

Results

1. Reduction in hippocampus blood flow is associated with depressive symptoms and cognitive impairment in chronic heart failure patients.

Results date posted

2021 Year 08 Month 15 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

Stage B and C heart failure patients (N=40) with 65.0+-10.9 (men) and 66.8+-8.9 (women) years of age.

Participant flow

We initially enrolled a total of 116 patients, including 56 with asymptomatic Stage B and 60 with symptomatic Stage C chronic heart failure from August 2012 to April 2013.
Of these, 18 patients withheld consent and 18 patients had ineligible or incomplete exams. Finally, 40 Stage B and 40 Stage C heart failure patients were analyzed.

Adverse events

No adverse events.

Outcome measures

Cerebral blood flow and brain grey and white matter volume or concentration

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2012 Year 06 Month 26 Day

Date of IRB

2012 Year 06 Month 15 Day

Anticipated trial start date

2012 Year 08 Month 01 Day

Last follow-up date

2013 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Patients' information is blinded to a person analyzing data of brain and cardiac MRI


Management information

Registered date

2012 Year 07 Month 31 Day

Last modified on

2021 Year 08 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010083


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name